Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Attovia Therapeutics to Participate in Upcoming Investor Conferences

globenewswire.com
ATTO The article announces Attovia Therapeutics' participation in upcoming investor conferences, which is a standard corporate event. It does not provide any new information about the company's performance, pipeline, or market outlook that would indicate a specific sentiment.

Attovia Therapeutics to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:

Citi’s 2026 Biopharma Back to School Conference

Format: 1x1 meetings

Date: Thursday, September 10, 2026

Morgan Stanley 24th Annual Global Healthcare Conference

Format: Fireside Chat

Date: Wednesday, September 16, 2026

Time: 10:00 AM - 10:35 AM EST

The webcast of the Morgan Stanley fireside chat will be accessible on the investor section of Attovia’s website. A replay of the webcast will be available for approximately 90 days following the conference.

About Attovia Therapeutics, Inc.

Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY™ biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.

Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.

Investor and Media Contact

Attovia Therapeutics

ir@attovia.com

PJ Kelleher

LifeSci Advisors LLC

617-430-7579

pkelleher@lifesciadvisors.com